Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541955 · ClinicalTrials.gov registry record · Phase 4
Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
A Phase 4 study, sponsored by Veena Ranganath, MD, MS.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02541955 is a Phase 4 study that has completed, run by Veena Ranganath, MD, MS. The registered enrollment target is 40 participants.
The verdict
NCT02541955, a Phase 4 study, has completed, sponsored by Veena Ranganath, MD, MS.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
Interventions
- DRUG Acthar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02541955
The ClinicalTrials.gov registry entry for NCT02541955 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veena Ranganath, MD, MS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acthar is the first listed.
NCT02541955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02541955 about?
NCT02541955 is a clinical study titled "Use of Acthar in Rheumatoid Arthritis (RA) Related Flares". This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
What is the current status of trial NCT02541955?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-07-20. Estimated completion is 2025-05-20.
What interventions are being tested in trial NCT02541955?
The interventions under investigation include: Acthar (DRUG).
Who is sponsoring clinical trial NCT02541955?
This trial is sponsored by Veena Ranganath, MD, MS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.